If Europe is to ensure that the latest therapies can be made available to all cancer patients who might benefit, getting maximum value from every euro spent on health will be essential. But who is to adjudicate that one patient can’t have something they need, because another with different needs could derive greater benefit for the same money?
Leave a Reply